---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-000610"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2026-02-03T23:59:59+00:00"
generated_at: "2026-05-16T05:21:36.129062+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioNexus begins VitaGuard MRD deployment in Southeast Asia; aims to undercut $3,000 legacy tests

## Summary
- Initial deployments in select Southeast Asian medical hubs during 2026; platform targets under $3,000 per test vs legacy costs often exceeding $3,000.
- Annual cancer incidence in region projected at 2.4M cases by 2030; company sees multi-billion-dollar market shift.
- Fidelion Diagnostics Pte. Ltd. established as exclusive IP and commercialization vehicle outside Greater China.
- Foundational steps completed by end 2025: global patent filings, recruitment, and regulatory prep with regional diagnostics partner.

## SEC filing metadata
- accession: 0001477932-26-000610
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2026-02-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793226000610/0001477932-26-000610-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793226000610/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-000610
- JSON: https://secwatch.observer/filing/0001477932-26-000610.json
- Plain text: https://secwatch.observer/filing/0001477932-26-000610.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.